NCI Seeks Partner to Market Molecular Dx That Can Identify Patients Prone to Adverse Events on Taxol | GenomeWeb
A research group from the National Cancer Institute is trying to outlicense a SNP-based diagnostic that it claims can help predict side effect response to paclitaxel, a widely prescribed chemotherapeutic.
 
The William Figg lab at NCI’s Center for Cancer Research is looking to license the technology, which is based on three SNPs in the ABCB1 gene that are linked to a range of drug-related side effects.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.